Ann: FDA Orphan Drug Designation for AD-214, page-19

Exactly mate. Too much upside when a stock hasn’t run yet. Happy to stick my money in a biotech that hasn’t run away yet. 30% is pretty good returns in a year....though 300% returns is alway possible when you put your money in a 40 million MC company. If you get in before the crowd it’s always easy to make profits. 1AD already has a commmercial collaboration with a trillion dollar revenue company in GE healthcare. 40 million MC collaborating with one of the largest healthcare companies in the world. If GE healthcare sees something in Adalta who am I to doubt? Will hold this one as long as they keep progressing like they are at the moment.